Liraglutide vs Syn-Ake
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Syn-Ake
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide that mimics the effect of Waglerin-1, a peptide found in Temple Viper venom. It's used in cosmetics for anti-wrinkle effects.
Full details →Side-by-Side Comparison
| Aspect | Liraglutide | Syn-Ake |
|---|---|---|
| Mechanism | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. | Acts as a competitive antagonist at the nicotinic acetylcholine receptor, reducing muscle contractions similar to Botox but through a different mechanism. Provides muscle-relaxing effects when applied topically. |
| Typical Dosage | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. | Topical: 1-4% concentration in serums or creams. Applied 1-2 times daily to target areas like forehead and crow's feet. |
| Administration | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. | Topical application only. Should be applied to clean skin. Often combined with other anti-aging peptides for synergistic effects. |
| Side Effects | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. | Generally well-tolerated topically. Rare reports of mild skin irritation or sensitivity. |
| Best For |